Home > Oncology > SABCS 2021 > Miscellaneous > Sentinel lymph node staging is non-inferior to complete axillary lymph node dissection

Sentinel lymph node staging is non-inferior to complete axillary lymph node dissection

Presented By
Dr Damiano Gentile, Humanitas Research Hospital, Italy
Conference
SABCS 2021
Trial
SINODAR ONE
Axillary lymph node dissection (ALND) is an effective procedure for axillary staging. However, it is associated with a significant risk of morbidity. The minimal invasive and less morbid sentinel lymph node biopsy (SLNB) is non-inferior to ALND, results of the SINODAR ONE trial show. Sentinel lymph node (SLN) staging is currently used to avoid complete ALND in breast cancer patients. The SLN is the only site of axillary metastasis in ≥60% of cases. Therefore, the SINODAR ONE study (NCT05160324) evaluated whether SLNB is or is not inferior to ALND. The study enrolled 889 patients between 40–75 years with a primary invasive T1-T2 tumour, axillary nodes cN0, no more than 2 macro-metastatic SLNs, no distant metastasis, no neo-adjuvant therapy, and no previous invasive breast cancer. All patients underwent SLNB and were randomis...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on